In the following years, more tumor-agnostic therapies were approved by the FDA, including targeted therapies (BRAF V600E, RET fusion), immunotherapies (tumor mutational burden ≥10 mutations per megabase, dMMR) and an antibody-drug conjugate (Her2-positive-immunohistochemistry 3+ expression) with pan-cancer efficacy [280]. This evidence concerns the gene RET and neoplasm.